NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Organogenesis Holdings Inc. (ORGO) Stock Analysis

Organogenesis Holdings Inc. (ORGO) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ORGO

$0.99

−$0.03 (−2.81%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ORGO with… →

ORGO Key Statistics

As of Oct 21, 2026
Trading
Open
$1.04
Previous Close
$1.02
Day's Range
0.96–1.06
52-Week Range
0.93–7.08
Volume
1.15M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.27
Valuation
Market Cap
$127.56M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.28
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.83
Financials (FY)
Revenue (FY)
$563.03M+16.80%
Net Income (FY)
$37.03M+4,201.05%
Profit marginThe share of revenue left as profit after all costs and taxes.
−18.40%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
128.67M
1-Year Return
−75.64%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
787.29K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ORGO closed at $0.99, −75.64% over 1 year.

Organogenesis Holdings Inc. (ORGO) has a market capitalization of $127.56M.

In fiscal 2025, ORGO reported revenue of $563.03M.

ORGO Stock Return by Calendar Year

Organogenesis Holdings Inc. (ORGO) return since Jan 2017: what $10,000 became

1 year
$10,000 $2,436
−75.64%
5 years
$10,000 $916
−90.84%
Since Jan 2017
$10,000 $1,017
−89.83%

If you had invested $10,000 in Organogenesis Holdings Inc. (ORGO) at the close on January 5, 2017, the earliest close on record here, it would have been worth $1,017 at the close on October 21, 2026: −89.83% in total, −20.82% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−80.86%
2025+61.87%
2024−21.76%
2023+52.04%
2022−70.89%
2021+22.71%
2020+56.55%
2019−52.61%
2018+2.32%
2017+1.74%

As of October 21, 2026.

ORGO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$563.03M$37.03M6.6%
2024$482.04M$861.00K0.2%
2023$433.14M$4.95M1.1%
2022$450.89M$15.53M3.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$563.03M$425.51M$55.87M$37.03M6.6%
2024$482.04M$366.30M$21.52M$861.00K0.2%
2023$433.14M$326.66M$12.53M$4.95M1.1%
2022$450.89M$345.87M$22.30M$15.53M3.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ORGO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricORGODrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.282.100.1x the median
Profit margin−18.40%−8.14%10.3 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Organogenesis Holdings Inc. (ORGO) is capitalised at $127.56M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 854.

The 52-week range on file runs from $0.93 to $7.08. The most recent close on file for ORGO is $0.99, dated October 21, 2026. That is −$0.03 (−2.81%) against the previous close. The latest close sits 6.71% above that 52-week low.

Financial Health

In fiscal 2025, Organogenesis Holdings Inc. reported revenue of $563.03M. Against the prior fiscal year total of $482.04M, that is a change of +16.80%. The same year closed with net income of $37.03M. That is +4,201.05% against the prior fiscal year. The reported profit margin is −18.4%. That is 10.3 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are −0.83.

Across the 4 fiscal years on file, revenue moves from $450.89M in 2022 to $563.03M in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 0.28. On price-to-sales that is 0.1 times the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.27. Daily returns over the trailing 9 years annualize to a volatility of 194.49%. Over the trailing twelve months the total return is −75.64%. Measured over 5 years, that is −38.00% a year compounded.

Growth & Income

No dividend is on file for ORGO.

So far in 2026 the total return is −80.86%. The strongest complete calendar year on file is 2025 at +61.87%; the weakest is 2022 at −70.89%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Organogenesis Holdings Inc. (ORGO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Organogenesis Holdings Inc. ORGO $127.56M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Organogenesis Holdings Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.

Visit website →